GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Cash Flow from Investing

PTGX (Protagonist Therapeutics) Cash Flow from Investing : $-299.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2024, Protagonist Therapeutics spent $0.3 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $114.4 Mil on purchasing investments. It gained $106.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Protagonist Therapeutics spent $8.7 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2024.


Protagonist Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Protagonist Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Cash Flow from Investing Chart

Protagonist Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.97 -15.86 91.47 -39.26 -299.48

Protagonist Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.29 6.07 -88.12 -208.71 -8.73

Protagonist Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Protagonist Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Protagonist Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-299.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protagonist Therapeutics  (NAS:PTGX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Protagonist Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2024 was $-0.3 Mil. It means Protagonist Therapeutics spent $0.3 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Protagonist Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2024 was $0.0 Mil. It means Protagonist Therapeutics gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Protagonist Therapeutics's purchase of business for the three months ended in Dec. 2024 was $0.0 Mil. It means Protagonist Therapeutics spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Protagonist Therapeutics's sale of business for the three months ended in Dec. 2024 was $0.0 Mil. It means Protagonist Therapeutics gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Protagonist Therapeutics's purchase of investment for the three months ended in Dec. 2024 was $-114.4 Mil. It means Protagonist Therapeutics spent {stock_data.stock.currency_symbol}}114.4 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Protagonist Therapeutics's sale of investment for the three months ended in Dec. 2024 was $106.0 Mil. It means Protagonist Therapeutics gained $106.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Protagonist Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2024 was $0.0 Mil. It means Protagonist Therapeutics paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Protagonist Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2024 was 0.0 Mil. It means Protagonist Therapeutics paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Protagonist Therapeutics's cash from other investing activities for the three months ended in Dec. 2024 was $0.0 Mil. It means Protagonist Therapeutics paid $0.0 Mil for other investing activities.


Protagonist Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick director
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035